San Francisco, United States
Syapse, founded in 2008, is an innovative Real-World Evidence (RWE) company based in the United States. Focusing on transforming real-world evidence into actionable insights, Syapse aims to alleviate the burden of serious diseases by advancing real-world care.
The company emphasizes precise and impactful care by facilitating collaboration among healthcare organizations, thereby empowering them to deliver comprehensive patient insights. This approach is particularly meaningful for cancer care and extends benefits to other serious disease areas.
In a bid to further its mission, Syapse secured a $35.00M Venture Round investment on July 27, 2022. This round saw participation from notable investors including Social Capital, Safeguard Scientifics, Ally Bridge Group, Innovatus Capital Partners, Northpond Ventures, Revelation Partners, and Merck Global Health Innovation Fund. These strategic investors underline the confidence in Syapse’s potential to drive meaningful advancements in healthcare.
